Biomarkers are provided that predict whether a human subject having a renal cell carcinoma is responsive to a combination therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate) and everolimus. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing a renal cell carcinoma.

A composition containing a chemokine inhibitor, a colony stimulating factor inhibitor, and an cancer immunotherapy agent, and a method for treatment of cancer, and a combination therapy are disclosed. The composition containing a CXCL12 inhibitor, a colony stimulating factor 1 (CSF1) inhibitor, and a cancer immunotherapy agent, for prevention and/or treatment of cancer, increases the infiltration and activity of CD8 cytotoxic T cells in cancers resistant to cancer immunotherapy agents, especially PD-1/PD-L1 immune checkpoint inhibitors, to effectively reduce tumor sizes and thus is useful for prevention and treatment of cancers resistant to immunotherapy agents, especially cancers overexpressing p16.sup.INK4A.

The present application relates to methods, reagents and kits for the assessment of the severity of nonalcoholic fatty liver disease (NAFLD) in a patient over time, and/or of the likelihood that a subject suffers from NAFLD. The methods, reagents and kits are based on the determination of the levels of VEGFA, TGFB1, and/or CSF1 in a biological sample, such as a plasma sample, from the subject. The methods, reagents and kits may be used, for example, for assessing the progression of NAFLD in a patient and/or the response of the patient to therapy.

Methods, systems, and kits for detection, diagnosis, monitoring, and/or treatment of viral infections such as represented by the COVID-19 disease are described. The methods, systems, and kits are capable of detection of salivary biomarkers which correlate with, and are indicative of, COVID-19 in a subject. Detection of the biomarkers in a saliva sample provides opportunities for a COVID-19 or other viral detection assay which is non-invasive, produces rapid results, and can be implemented in the field on a wide geographic basis for individualized screening or mass screenings for COVID-19 or other viral infections.

Provided herein are methods, kits, and pharmaceutical compositions that include a P13 kinase inhibitor for treating cancers or hematologic disorders.

The present disclosure teaches an assay to determine the likelihood of a successful implantation of an embryo into a female subject leading to a pregnancy and a method of treatment to facilitate same. Enabled herein is an improved assisted reproduction technology protocol based on a prognostic evaluation of pregnancy outcomes and the identification of therapeutic targets. Taught herein is a composition comprising reagents required for prognostic evaluation and treatment.

Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating cancers or hematologic disorders.

The invention is directed to methods and systems for carrying out one or more highly multiplexed cellular assays. In some embodiments, one or more channels of a fluidic device are provided with photopolymerizable polymer precursors and cells randomly disposed on a surface, after which positions of cells are measured by a detector, hydrogel chambers are synthesized by photopolymerization to enclose individual cells, and channels are loaded with assay reagents. Assay signals indicative of desired cellular characteristics can be generated for each of the enclosed cells.

Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating cancers or hematologic disorders.

Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating cancers or hematologic disorders.